Myriad Genetics Corporate Presentation 6/4/13
|
|
- Cleopatra Howard
- 5 years ago
- Views:
Transcription
1 Myriad Genetics Corporate Presentation 6/4/13
2 Forward Looking Statement Some of the information presented here today may contain projections or other forward-looking statements regarding future events or the future financial performance of the Company. These statements are based on management s current expectations and the actual events or results may differ materially and adversely from these expectations. We refer you to the documents the Company files from time to time with the Securities and Exchange Commission, specifically, the Company s annual reports on Form 10-K, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. These documents identify important risk factors that could cause the actual results to differ materially from those contained in the Company s projections or forward-looking statements.
3 Well-Positioned Industry Leader Myriad Genetics is dedicated to saving lives and improving the quality of life of patients through the discovery and commercialization of novel, transformative diagnostic tests across all major diseases Myriad is focused on every aspect of the disease process across the continuum of complete patient care Assessing risk of disease Ensuring rapid & accurate diagnosis Predicting progression Guiding treatment decisions
4 Multiple Growth Opportunities Business Strategy Growing Existing Markets Expanding Global Presence Launching New Products Fuel Strong Long-Term Top Line Growth
5 Broadening Disease Focus Current Markets Future Markets Preventive Care Urology Oncology Oncology Preventive Care Urology Dermatology Autoimmune Neuroscience Developing Tests Across Multiple Diseases
6 Myriad International Network Myriad products are now represented in > 80 countries by 40 distributors MYGN Direct Distribution MYGN Distributor Country
7 The Myriad Vision A TRUSTED ADVISOR ANSWERING PATIENT S MOST PRESSING CONCERNS RISK ASSESSMENT GUIDE THERAPY DIAGNOSIS COMPLETE PATIENT CARE PROGRESSION
8 First Patient Concern; What s My Risk? Identifying hereditary disease saves lives Future of genetic testing is pan-disease panels Myriad s myrisk Hereditary Cancer test will be first comprehensive pan-cancer panel 100% 75% 82% 71% 87% 75% General Population Risk 50% 44% Hereditary Cancer Risk 25% 0% 5% Colorectal Cancer Risk 1% 2% 1% Endometrial Cancer Risk 12% 5% 5% 1% 2% 1% Breast Cancer Risk Ovarian Cancer Risk Melanoma Risk Risk With Preventive Measures
9 Solution: myrisk Hereditary Cancer Product Profile: 25 gene panel (sequencing + large rearrangements) Clinically actionable genes (current genes + others) Initial focus on breast, colon, ovarian, endometrial, pancreatic, and melanoma Future expansion to lung, prostate, all cancers Turn around time 14 days or less List price between $4,000 and $4,500 Projected gross margin of 87%
10 myrisk Hereditary Cancer Market Expansion Eligible Patients Cancer Indications Health Economics Increased sensitivity expands criteria New genes expand cancer indications Comprehensive cancer risk report Improves health economics
11 Expansion Phase: New Indications ONCOLOGY CURRENT: 300,000 per year BREAST 30% COLON 25% OVARIAN 100% FY16: 600,000 per year BREAST 60% COLON 60% OVARIAN 60% ENDO 60% Pancreas 60% Melanoma 60% CANCER SCREEN = 1.6 MILLION PATIENTS
12 Differentiation Phase: Trusted Advisor Competitors Miss 60% of Positives Health Economics MUST KNOW True Positives prevent cancer True Negatives avoid unecessary screening and surgery FOUND MISSED (myrisk) MISSED (BART) MISSED (Database)
13 Solution: myrisk Hereditary Cancer Strategic Objectives: Launch in Fall of 2013 Convert entire hereditary cancer market by summer 2015 and discontinue BRACAnalysis, COLARIS, COLARIS AP, Melaris, and Panexia Proprietary Genes: Current: BRCA1, BRCA2, BART, RAD51C, PALB2, PTEN, MYH, P16 Future: MITF, ELAC2, others
14 Second Patient Concern; Do I Have Disease? Cancer diagnosis today involves considerable judgment Future of cancer diagnosis will use molecular diagnostics for more accurate detection 14% of All Skin Biopsies Are Indeterminate 14% Quicker and more accurate diagnosis like MelaPath saves lives and improves patient healthcare 86%
15 Third Patient Concern; How Aggressive is My Disease? Physicians have difficulty accurately predicting whether or not patient s disease will progress 100% PROLARIS Predicts Prostate Cancer Survival 90% Physicians don t know how aggressively to treat patients and frequently over-treat patients Molecular diagnostic tests like PROLARIS will save lives, improve quality of life, and reduce healthcare costs Prostate Cancer Survival Over 10 Years (%) 75% 50% 25% 0% Low PROLARIS Score 22% High PROLARIS Score
16 PROLARIS Competitive Advantages PROLARIS Indications Biopsy, Prostatectomy Outcome Predicted Patients Studied Gold standard outcomes: Risk of PrCa-specific mortality, metastasis, biochemical recurrence Over 3,000 Published Studies Add l Studies Presented Heterogeneity Sample Requirements accepted 4 Genes show little regional variability Smallest in the industry (20 microns)
17 Queen Mary University of London Study Published in the British Journal of Cancer 100% Study Details N=349 patients Sample type: Biopsy Outcome: Survival Published in the BJC 10-Year Survival 75% 50% 25% 80% 25% 0% Low-Risk PROLARIS Score High-Risk PROLARIS Score
18 PROLARIS Progress To Date Received over 3,000 orders in the last 12 months Significantly better than any other cancer prognostic launch Approximately 90% of current samples are biopsy tissue Received samples from over 350 urologists 24 person sales force PROCEDE data to Medicare by summer 2013 Medicare reimbursement expected in CY14
19 Fourth Patient Concern; What Therapy is Best? Many medicines today are prescribed on a trial and error basis Only about 30% of cancer patients will benefit from any particular chemotherapy Future of drug development is using companion diagnostics to identify responders and non-responders Technology is progressing beyond single-gene biomarkers to focus on disease pathways like Myriad s HRD test Percent of Patients Responding 100% 75% 50% 25% 0% Carboplatin Based Therapy 70% 12% HRD Score > 10 HRD Score < 10
20 Inability to Repair DNA Prevalent in Major Cancers Ovarian tumors (n=747) Esophagus tumors (n=51) Lung tumors (n=226) Brain cell lines (n=19) Prostate tumors (n=23) Colon cell lines (n=42) 490,000 Candidate Patients Per Year = $1B to $2B U.S. Market Opportunity 0% 5% 10% 15% 20% 25% 30% 35% 40% 45% 50% % of Samples With HRD Score > 10
21 Multiple Companion Diagnostic Partnerships Multiple Billion Dollar Markets Pre-IND Phase 1 Phase 2 Phase 3 Post- Marketing Stage Projects Areas Phase II 8 Oncology, Neuropsychiatry Phase III 3 Neuropsychiatry Post-Marketing 3 Neuropsychiatry, Kidney Damage
22 AstraZeneca PARP (Olaparib) Launch: 2015 Olaparib in ovarian cancer: EMA filing in 2013, launch in 2015 EU opportunity for BRCA testing ~30,000 tests/year or $120 million/year Requires BRCA testing with high accuracy & fast turnaround time (< 14days and < 3% VUS rate) Other Solid Tumors Lung Cancer Ovarian Cancer HRD Impaired Cancer Gastric Cancer Advanced Breast Cancer Early TN Breast Cancer Opportunities beyond ovarian cancer Myriad is only Company that can achieve turnaround times and accuracy needed for a companion launch
23 Projected Change in Market Opportunity 2013 Global Market Size = $4.2 Billion 2018 Global Market Size = $12.1 Billion $0.4 $1.8 $0.7 $1.2 $2.0 $0.8 $1.4 $3.0 $5.0 BRACAnalysis COLARIS myrisk Cancer PROLARIS Other HRD MelaPath
24 Historical Financial Performance $600 Revenue Growth $200 Operating Income $500 $400 $300 $200 22% CAGR $150 $100 $50 31% CAGR $100 FY08 FY09 FY10 FY11 FY12 $0 FY08 FY09 FY10 FY11 FY12 PF EPS Quarterly ROIC $1.50 $1.25 $ % CAGR 26.0% 24.0% 22.0% 21.1% 24.0% 23.2% 23.5% $ % $ % $0.25 FY08 FY09 FY10 FY11 FY % 4Q12 1Q13 2Q13 3Q13
25 Fiscal Year 2013 Guidance Range Growth MDx Revenue: $560M - $572M 19-21% CDx Revenue: $25M - $28M 19-27% Total Revenue: $595M - $600M 20-21% Diluted EPS: $ $ %
26 Myriad Core Competencies Content Driven Company: Leader in disease profiling Pioneer in understanding cancer risk: Launch myrisk Hereditary Cancer test this fall First comprehensive pan-cancer panel Innovator in companion diagnostics: Launch HRD test in CY2015 for platinum therapies Will revolutionize cancer treatment Trailblazer in guiding threapy: Over 3,000 PROLARIS test orders year-to-date Expect broad reimbursement coverage within 12 months Most Comprehensive Capabilities: Multiple biomarker tools (DNA, RNA, and protein)
Myriad Genetics Fiscal First-Quarter 2017 Earnings Call 11/01/2016
Myriad Genetics Fiscal First-Quarter 2017 Earnings Call 11/01/2016 1 Forward Looking Statements Forward Looking Statements Some of the information presented here today may contain projections or other
More informationMedia Contact: Ron Rogers Investor Contact: Scott Gleason (801) (801)
News Release Media Contact: Ron Rogers Investor Contact: Scott Gleason (801) 584-3065 (801) 584-1143 rrogers@myriad.com sgleason@myriad.com Myriad Receives FDA Approval of BRACAnalysis CDx as Companion
More informationMyriad Genetics Corporate Presentation 06/13/2018
Myriad Genetics Corporate Presentation 06/13/2018 Copyright 2016 2018 Myriad Genetics, Inc., all rights reserved. www.myriad.com. 1 Forward Looking Statements Some of the information presented here today
More informationMyriad Genetics mychoice HRD Update 06/30/2016
Myriad Genetics mychoice HRD Update 06/30/2016 1 Forward Looking Statements Some of the information presented here today may contain projections or other forward-looking statements regarding future events
More informationMyriad Genetics Fiscal First-Quarter 2019 Earnings Call 11/06/2018
Myriad Genetics Fiscal First-Quarter 2019 Earnings Call 11/06/2018 Copyright 2017 2018 Myriad Genetics, Inc., all rights reserved. www.myriad.com. 1 Forward Looking Statements Forward Looking Statements
More informationMyriad Genetics Fiscal Third-Quarter 2017 Earnings Call 05/02/2017
Myriad Genetics Fiscal Third-Quarter 2017 Earnings Call 05/02/2017 1 Forward Looking Statements Forward Looking Statements Some of the information presented here today may contain projections or other
More informationMyriad Financial Assistance Program (MFAP)
Myriad Financial Assistance Program (MFAP) MEDICAL CRITERIA Hereditary Cancer Products The Myriad Financial Assistance Program offers aid to patients who meet specific financial and medical requirements.
More informationHereditary Cancer Products
Hereditary Products Integrated BRACAnalysis (BRCA1 and BRCA2 sequencing and large rearrangement testing (BART)), covered when: PERSONAL HISTORY of Breast (must meet at least 1) Diagnosed
More information37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE
37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE January 2019 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as
More informationMyriad Genetics Fiscal Second-Quarter 2017 Earnings Call 02/07/2017
Myriad Genetics Fiscal Second-Quarter 2017 Earnings Call 02/07/2017 1 Forward Looking Statements Forward Looking Statements Some of the information presented here today may contain projections or other
More informationForward Looking Statements
Forward Looking Statements Some of the information presented here today may contain projections or other forward-looking statements regarding future events or the future financial performance 15M Patient
More informationLiquid Biopsies. Next Generation Cancer Molecular Diagnostics
Liquid Biopsies Next Generation Cancer Molecular Diagnostics Forward Looking Statements 2 Statements pertaining to future financial and/or operating results, future research, diagnostic tests and technology
More informationGenomic Health. Kim Popovits, Chairman, CEO and President
Genomic Health Kim Popovits, Chairman, CEO and President Safe Harbor Statement Various remarks that we make in this presentation that are not historical, including those about our future financial and
More informationCorporate Presentation. June 2017
v Corporate Presentation June 2017 Safe harbor statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E
More information(MYGN - $34.67 NASDAQ)
G.research, Inc. One Corporate Center Rye, NY 10580-1422 Tel (914) 921-5075 www.gabelli.com July 21, 2015 Gabelli & Company Myriad Genetics (MYGN - $34.67 NASDAQ) Source: Myriad Genetics Slowly But Surely
More informationCorporate Presentation Fourth Quarter 2017
Corporate Presentation Fourth Quarter 2017 November 2017 1 Safe harbor statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as
More information33 rd Annual J.P. Morgan Healthcare Conference. January 2015
33 rd Annual J.P. Morgan Healthcare Conference January 2015 Forward-looking Statements This presentation contains forward-looking statements, which express the current beliefs and expectations of management.
More information36th Annual J.P. Morgan Healthcare Conference. Kevin Conroy, Chairman and CEO January 9, 2018
36th Annual J.P. Morgan Healthcare Conference Kevin Conroy, Chairman and CEO January 9, 2018 1 Safe harbor statement This presentation contains forward-looking statements within the meaning of Section
More informationClovis Oncology Announces First Quarter 2017 Operating Results. May 3, :06 PM ET
Clovis Oncology Announces First Quarter 2017 Operating Results May 3, 2017 4:06 PM ET Strong Q1 launch quarter for Rubraca (rucaparib) in U.S. with $7M reported in net sales Clovis notified that ARIEL3
More informationMEDICAL POLICY Genetic Testing for Breast and Ovarian Cancers
POLICY: PG0067 ORIGINAL EFFECTIVE: 07/30/02 LAST REVIEW: 01/25/18 MEDICAL POLICY Genetic Testing for Breast and Ovarian Cancers GUIDELINES This policy does not certify benefits or authorization of benefits,
More informationThird Quarter 2015 Earnings Call. November 9, 2015
Third Quarter 2015 Earnings Call November 9, 2015 Forward-Looking Statements All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements
More informationBe Ready Pack Learn more about how Myriad myrisk is revolutionizing hereditary cancer testing.
Be Ready Pack Learn more about how Myriad myrisk is revolutionizing hereditary cancer testing. Hereditary cancer and you Approximately 5% to 10% of all cancers develop because a person inherited a genetic
More informationBank of America 38 th Annual Investment Conference. San Francisco, CA September 17 th, 2008
Bank of America 38 th Annual Investment Conference 1 San Francisco, CA September 17 th, 2008 Introduction This slide presentation contains forward-looking statements which are subject to change based on
More informationClovis Oncology Announces Q Operating Results and Corporate Update. November 3, :05 PM ET
Clovis Oncology Announces Q3 2016 Operating Results and Corporate Update November 3, 2016 4:05 PM ET Rucaparib New Drug Application (NDA) accepted for Priority Review in the treatment of advanced BRCA-mutant
More informationJ.P. Morgan. 27 th Annual Healthcare Conference. San Francisco January 14 th, 2009
J.P. Morgan 27 th Annual Healthcare Conference 1 San Francisco January 14 th, 2009 Introduction This slide presentation contains forward-looking statements which are subject to change based on various
More informationWells Fargo Healthcare Conference September 6, 2018
Wells Fargo Healthcare Conference September 6, 2018 Safe Harbor Statement To the extent that statements contained in this presentation are not descriptions of historical facts regarding TESARO, they are
More informationMolecular Diagnostic Solutions for Urologic Cancer
1 Molecular Diagnostic Solutions for Urologic Cancer 2017 First Half Results Presented on 31 August 2017 Dr. Jan Groen, President & CEO Mr. Jean-Marc Roelandt, EVP & CFO 2 Forward looking statement This
More informationVAL-083: Validated DNA-targeting Agent for Underserved Cancer Patients. September 2018
VAL-083: Validated DNA-targeting Agent for Underserved Cancer Patients September 2018 Forward-Looking Statements Any statements contained in this presentation that do not describe historical facts may
More informationWHAT IS A GENE? CHROMOSOME DNA PROTEIN. A gene is made up of DNA. It carries instructions to make proteins.
WHAT IS A GENE? CHROMOSOME E GEN DNA A gene is made up of DNA. It carries instructions to make proteins. The proteins have specific jobs that help your body work normally. PROTEIN 1 WHAT HAPPENS WHEN THERE
More informationBuilding a Premier Oncology Biotech
Corporate Deck Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO November 2018 Forward-Looking Statements All of the statements in this presentation that are not statements of historical
More informationGenetic Testing: who, what, why?
Genetic Testing: who, what, why? Gina Westhoff MD LMG Gynecologic Oncology March 16, 2019 Disclosures Speaker for Merck (unrelated to today s topic) Objectives Determine who should undergo genetic risk
More informationDeveloping & Commercializing Targeted Small Molecule Drugs in Cancer
Developing & Commercializing Targeted Small Molecule Drugs in Cancer SAFE HARBOR STATEMENT 2 Forward-looking statements made in the course of this presentation are made pursuant to the safe harbor provisions
More informationUroplasty, Inc. Investor Update Canaccord Genuity Conference December 6, 2011
Uroplasty, Inc. Investor Update Canaccord Genuity Conference December 6, 2011 Forward Looking Statement This presentation includes forward-looking statements, including financial projections, relating
More informationBuilding a Premier Oncology Biotech
Wells Fargo Securities Healthcare Conference Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO September 2018 Forward-Looking Statements All of the statements in this presentation
More informationNektar Investor & Analyst Call. Nektar & z Bristol-Myers Squibb Collaboration. February 14, 2018
Nektar Investor & Analyst Call Nektar & z Bristol-Myers Squibb Collaboration February 14, 2018 This presentation includes forward-looking statements regarding Nektar s proprietary drug candidates, the
More informationPositioned for Growth
Positioned for Growth Annual Shareholders Meeting July 21, 2016 Paris Panayiotopoulos President and Chief Executive Officer David Sachs Non small cell lung cancer ARIAD clinical trial patient This presentation
More informationWhen the question is genetics, the answer is Invitae Invitae Corporation. All Rights Reserved. 1
When the question is genetics, the answer is Invitae. L A D E N B U R G T H A L M A N N 2 0 1 8 H E A LT H C A R E C O N F E R E N C E S E A N G E O R G E, C H I E F E X E C U T I V E O F F I C E R 2018
More informationHALOZYME REPORTS SECOND QUARTER 2018 RESULTS
Contacts: Robert H. Uhl Managing Director Westwicke Partners, LLC 858-356-5932 robert.uhl@westwicke.com Laurie Stelzer 858-704-8222 ir@halozyme.com FOR IMMEDIATE RELEASE HALOZYME REPORTS SECOND QUARTER
More informationCorporate Presentation. August 2016
v Corporate Presentation August 2016 Safe harbor statement Certain statements made in this presentation contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933,
More informationCorporate Presentation. First Quarter 2018
Corporate Presentation First Quarter 2018 1 Safe harbor statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and
More informationInvestor Call. May 19, Nasdaq: IMGN
Investor Call May 19, 2017 Nasdaq: IMGN Forward-Looking Statements This presentation includes forward-looking statements based on management's current expectations. These statements include, but are not
More informationMERCK ONCOLOGY OVERVIEW ASCO 2018 JUNE 4, 2018
MERCK ONCOLOGY OVERVIEW ASCO 218 JUNE 4, 218 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA This presentation of Merck & Co., Inc., Kenilworth, N.J., USA (the company ) includes forward
More informationVeriStrat Poor Patients Show Encouraging Overall Survival and Progression Free Survival Signal; Confirmatory Phase 2 Study Planned by Year-End
AVEO and Biodesix Announce Exploratory Analysis of VeriStrat-Selected Patients with Non-Small Cell Lung Cancer in Phase 2 Study of Ficlatuzumab Presented at ESMO 2014 Congress VeriStrat Poor Patients Show
More informationBuilding a Premier Oncology Biotech
Building a Premier Oncology Biotech August 208 Forward-Looking Statements All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements within
More informationCorporate Presentation. Second Quarter 2018
Corporate Presentation Second Quarter 2018 1 Safe harbor statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and
More informationDisruptive innovation in molecular diagnostics. Hilde Windels CEO Biocartis 25 March 2017
Disruptive innovation in molecular diagnostics Hilde Windels CEO Biocartis 25 March 2017 1 One of the key innovations in healthcare in the last decade PERSONALISED MEDICINE or HIGH PRECISION MEDICINE From
More informationJanuary 30, 2018 Dow Wilson President and Chief Executive Officer
Acquisition of SIRTeX January 30, 2018 Dow Wilson President and Chief Executive Officer This presentation is intended exclusively for investors. It is not intended for use in Sales or Marketing. Forward-Looking
More informationAsia-Pacific Bariatric Surgery Devices Market Outlook to 2020
Asia-Pacific Bariatric Surgery Devices Market Outlook to 2020 Reference Code: GDMECR0195DB Publication Date: July 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 4 1.2 List
More informationGuardant Health Investor Presentation. January 2019
Guardant Health Investor Presentation January 2019 Safe harbor statement This presentation contains forward-looking statements, which are statements related to future events that by their nature address
More informationDiagnostics for the early detection and prevention of colon cancer. Leerink Swann Global Health Care Conference February 2015
Diagnostics for the early detection and prevention of colon cancer Leerink Swann Global Health Care Conference February 2015 Safe Harbor Statement Certain statements made in this news release contain forward-looking
More informationGenetic Testing Today: What Genes Can Tell Us. Living Beyond Breast Cancer Conference Kara N. Maxwell, MD, PhD University of Pennsylvania
Genetic Testing Today: What Genes Can Tell Us Living Beyond Breast Cancer Conference Kara N. Maxwell, MD, PhD University of Pennsylvania Overview of talk PART 1: Overview of Genetics PART 2: BRCA1/2 PART
More informationValue creation through profitable growth Handelsbanken Nordic Large Cap Seminar, Stockholm 2016 Anders Lonning-Skovgaard, CFO
Value creation through profitable growth Handelsbanken Nordic Large Cap Seminar, Stockholm 2016 Anders Lonning-Skovgaard, CFO Coloplast has four business areas all with global sales presence Group revenue
More informationOncology Therapeutics without Compromise APRIL 2011
Oncology Therapeutics without Compromise APRIL 2011 Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties, including among other
More informationLung Cancer Screening
Lung Cancer Screening v Lung Cancer: America s leading cancer killer Annual US cancer mortality 158,040 221,000 new diagnoses in US 4,100 14,180 27,540 Lung 40,560 40,730 49,700 Cervix Ovary Prostate Pancreas
More informationCorporate Presentation
Corporate Presentation January 2019 2018 Chembio. All Rights Reserved. # 2019 Chembio. All Rights Reserved. Page 1 Safe Harbor Statement Statements contained herein that are not historical facts are forward-looking
More informationALLERGAN TO ACQUIRE ZELTIQ FOR $2.47B BEST-IN-CLASS COMPANY IN FAST GROWING BODY CONTOURING SEGMENT
ALLERGAN TO ACQUIRE ZELTIQ FOR $2.47B BEST-IN-CLASS COMPANY IN FAST GROWING BODY CONTOURING SEGMENT ALLERGAN CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS Statements contained in this presentation
More informationArQule Jefferies Global Healthcare Conference June 2015
ArQule Jefferies Global Healthcare Conference June 2015 1 ArQule Corporate Update Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning
More informationFinancial Presentation
Financial Presentation Certain of the statements that will be made during this meeting, as well as statements contained in our 2006 Annual Report to Shareholders and Annual Report on Form 10-K filed with
More informationADM to Acquire Neovia and Probiotics International Limited. July 2, 2018
ADM to Acquire Neovia and Probiotics International Limited July 2, 2018 Safe Harbor Statement 2 Some of our comments constitute forward-looking statements that reflect management s current views and estimates
More informationThe 100,000 Genomes Project
The 100,000 Genomes Project Dr Matina Prapa, Scientific co ordinator Genomics England Clinical Interpretation Partnership William Harvey Research Institute Queen Mary University of London Genomics England
More informationFDA Companion Diagnostic Testing and Implications for Pharmacy and Medical Directors
FDA Companion Diagnostic Testing and Implications for Pharmacy and Medical Directors Diana Brixner, PhD, RPh, FAMCP Professor, University of Utah Health Sciences Executive Director, Pharmacotherapy Outcomes
More informationUniversal Biosensors, Inc.
Universal Biosensors, Inc. ARBN 121 559 993 Buchan Three Tickers Presentation 18 th September 2013 1 Important Disclaimer This presentation is intended to provide a general outline only and is not intended
More informationPresentation to AGM 9 November Deborah Rathjen CEO & Managing Director
Presentation to AGM 9 November 2011 Deborah Rathjen CEO & Managing Director Safe Harbor Statement Factors Affecting Future Performance This presentation contains "forward looking" statements within the
More informationONCOLOGY: WHEN EXPERTISE, EXPERIENCE AND DATA MATTER. KANTAR HEALTH ONCOLOGY SOLUTIONS: FOCUSED I DEDICATED I HERITAGE
CATALYSTS DRIVING SUCCESSFUL DECISIONS IN LIFE SCIENCES ONCOLOGY: WHEN EXPERTISE, EXPERIENCE AND DATA MATTER. KANTAR HEALTH ONCOLOGY SOLUTIONS: FOCUSED I DEDICATED I HERITAGE AT KANTAR HEALTH, ONCOLOGY
More information2018 Bank of America Merrill Lynch Healthcare Conference
CHANGING THE COURSE OF HUMAN HEALTH THROUGH BOLD PURSUITS IN SCIENCE 2018 Bank of America Merrill Lynch Healthcare Conference May 16, 2018 Forward-Looking Statements and Adjusted Financial Information
More informationGLOBAL & USA CANCER BIOMARKER MARKET to 2018
GLOBAL & USA CANCER BIOMARKER MARKET to 2018 (Identification, Technologies, Market Analysis, Competitor Profiles, Companion Diagnostic Co-Development, Business Strategies, Industry Trends, and Pipeline
More informationSpectrum Pharmaceuticals
Spectrum Pharmaceuticals Joe Turgeon President and CEO June 2018 Investor Presentation 1 Safe Harbor Statement This presentation contains forward looking statements regarding future events and the future
More informationOpportunities and Challenges in the Development of Companion Diagnostics
Opportunities and Challenges in the Development of Companion Diagnostics E. Patrick Groody, Ph.D. Divisional Vice President Research and Development Abbott Molecular Agenda Value of Personalized Medicine
More informationBRIC Transurethral Resection of the Prostate (TURP) Procedures Outlook to 2020
BRIC Transurethral Resection of the Prostate (TURP) Procedures Outlook Reference Code: GDMECR0130PDB Publication Date: July 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables...
More informationDS-8201 Strategic Collaboration
DS-8201 Strategic Collaboration DAIICHI SANKYO CO., LTD George Nakayama Chairman and CEO March 29, 2019 Forward-Looking Statements Management strategies and plans, financial forecasts, future projections
More informationEU5 Bariatric Surgery Procedures Outlook to 2020
EU5 Bariatric Surgery Procedures Outlook to 2020 Reference Code: GDMECR0089PDB Publication Date: July 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 3 1.2 List of Figures...
More informationFeasibility of Clinical Trial Implementation Genetically Eligible Prostate Cancer Patients Oliver Sartor, MD Cathryn E, Garvey, MS December 3, 2015
Feasibility of Clinical Trial Implementation Genetically Eligible Prostate Cancer Patients Oliver Sartor, MD Cathryn E, Garvey, MS December 3, 2015 Study Name Feasibility of Patient Population for proposed
More informationNatus Medical Incorporated. Jeffries Global Healthcare CONFERENCE Tuesday June 6, 2017
Natus Medical Incorporated Jeffries Global Healthcare CONFERENCE Tuesday June 6, 2017 Forward-Looking Statements This presentation contains forward-looking statements including statements regarding our
More informationAVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC
FOR IMMEDIATE RELEASE AVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC - Tivozanib is the First Agent to Demonstrate Greater than One Year
More informationVisionary Private Equity Group is Pleased to Announce its Investment in MEDITE Cancer Diagnostics
Dear VPEG Limited Partner, We hope this investor update finds you well. We're pleased to share with you an important update below on the following: Visionary Private Equity Group is Pleased to Announce
More informationST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015
ST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015 1 FORWARD LOOKING STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation
More informationForward Looking Information
Vital Signs, Inc. Forward Looking Information Except for historical information discussed, the statements made today are forward-looking statements that involve risks and uncertainties. Investors are cautioned
More informationMedSurg: Endoscopy Presentation for the Investment Community at DDW. Art Butcher Senior Vice President and President, Endoscopy
MedSurg: Endoscopy Presentation for the Investment Community at DDW Art Butcher Senior Vice President and President, Endoscopy Safe Harbor for Forward-Looking Statements This presentation contains forward-looking
More informationDawson James Conference
Dawson James Conference October 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV s current expectations regarding
More informationJanuary 2017 Investor Presentation. confidently live life with ease
January 2017 Investor Presentation confidently live life with ease Forward-Looking Statements This presentation contains certain forward-looking statements that involve risks and uncertainties that could
More informationPascal Soriot, Head of Strategic Marketing
Workshop Marketing a cancer drug Pascal Soriot, Head of Strategic Marketing Trends in the oncology market Europe/ RoW compared to US Marketing cancer drugs successfully Leveraging 1 st mover advantage
More informationOncology Therapeutics Market in India to 2018
Oncology Therapeutics Market in India to 2018 Introduction of Market-Based Pricing to Fuel Price Wars and Intense Competition Among Domestic and Multinational Players GBI Research Report Guidance GBI Research
More informationGenomics and Genetic Testing. Copyright 2017 Myriad Genetics, Inc., all rights reserved.
Genomics and Genetic Testing Copyright 2017 Myriad Genetics, Inc., all rights reserved. www.myriad.com Why is genetic testing important to you? Impact on immediate treatment decisions Identify risks for
More informationREFERENCE CODE GDHC200DFR PUBLICAT ION DATE JUNE 2013 AVASTIN (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC200DFR PUBLICAT ION DATE JUNE 2013 AVASTIN (NON-SMALL CELL LUNG CANCER) AVASTIN (NON-SMALL CELL LUNG CANCER) - Executive Summary Avastin (bevacizumab): Key Metrics in NSCLC Markets 2012
More information34 th Annual J.P. Morgan Healthcare Conference
JANUARY 2016 34 th Annual J.P. Morgan Healthcare Conference [ 1 ] Forward Looking Statements SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS In addition to historical information, this presentation contains
More informationRoche Diagnostics Daniel O Day COO Roche Diagnostics. Société Générale - The Premium Review Conference, Paris December 2, 2011
This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes, expects, anticipates, projects, intends, should, seeks, estimates,
More informationStrengthening our global leadership in treatment of addiction. Morgan Stanley Global Healthcare Conference September 13 th and 14 th 2018
Strengthening our global leadership in treatment of addiction Morgan Stanley Global Healthcare Conference September 13 th and 14 th 2018 Forward Looking Statements This presentation contains certain statements
More informationAccelerate Your Research with Conversant Bio
Imagination has given us the steam engine, the telephone, the talkingmachine and the automobile, for these things had to be dreamed of before they became realities. So I believe that dreams... are likely
More informationCLINICAL RESEARCH IN GEORGIA UPDATE. Nancy M. Paris, MS, FACHE President, Georgia CORE September 6, 2014
CLINICAL RESEARCH IN GEORGIA UPDATE Nancy M. Paris, MS, FACHE President, Georgia CORE September 6, 2014 Georgia CORE is a public-private partnership dedicated to generating collaborative resources for
More informationMerck ASCO 2015 Investor Briefing
Merck ASCO 2015 Investor Briefing Forward-Looking Statement This presentation includes forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation
More informationClinical Quality Assurance Measures at Myriad Genetic Laboratories:
Clinical Quality Assurance Measures at Myriad Genetic Laboratories: Increasing the Clinical Utility and Cost-Effectiveness of Genetic Testing for Hereditary Cancer Syndromes for Patients, Healthcare Providers
More informationREFERENCE CODE GDHC207DFR PUBLICAT ION DATE JUNE 2013 GILOTRIF (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC207DFR PUBLICAT ION DATE JUNE 2013 GILOTRIF (NON-SMALL CELL LUNG CANCER) GILOTRIF (NON-SMALL CELL LUNG CANCER) - Executive Summary Gilotrif: Key Metrics in NSCLC Markets 2022 Gilotrif
More informationExpanding the boundaries of nutrition Luis Cantarell
Expanding the boundaries of nutrition Luis Cantarell Nestlé Investor Seminar 30 September 2013 Disclaimer This presentation contains forward looking statements which reflect Management s current views
More informationInfinity Highlights Promising Preclinical Hedgehog Data and Announces First Quarter Financial Results
Infinity Highlights Promising Preclinical Hedgehog Data and Announces First Quarter Financial Results Heat Shock Protein 90 Program Continues to Advance Toward Potential Registration Trial CAMBRIDGE, Mass.,
More informationValue creation through profitable growth Danske Bank Winter Seminar 2017, Copenhagen Lars Rasmussen, President & CEO
Value creation through profitable growth Danske Bank Winter Seminar 2017, Copenhagen Lars Rasmussen, President & CEO Forward-looking statements The forward-looking statements contained in this presentation,
More informationREFERENCE CODE GDHC196DFR PUBLICAT ION DATE JUNE 2013 ABRAXANE (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC196DFR PUBLICAT ION DATE JUNE 2013 ABRAXANE (NON-SMALL CELL LUNG CANCER) Executive Summary Abraxane (nab-paclitaxel): Key Metrics in NSCLC Markets 2012 Abraxane Sales US 5EU $98.34m
More information- Plans Commercial Launch of three dosing options for Excellagen in pre-filled syringes
Generex Biotechnology Subsidiary Olaregen Therapeutix Inc. Plans Launch of FDA Cleared Excellagen Wound Conforming Gel Matrix with Three Dosage Options - Plans Commercial Launch of three dosing options
More informationAssessment and Management of Genetic Predisposition to Breast Cancer. Dr Munaza Ahmed Consultant Clinical Geneticist 2/7/18
Assessment and Management of Genetic Predisposition to Breast Cancer Dr Munaza Ahmed Consultant Clinical Geneticist 2/7/18 Overview The role of the Cancer Genetics team NICE guidelines for Familial Breast
More informationPhotocure ASA Executing the Strategy
Photocure ASA Executing the Strategy NOVEMBER 2012 ERIK DAHL, CFO KATHLEEN DEARDORFF, COO Disclaimer The information included in this Presentation contains certain forward-looking statements that address
More information